News
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies
JEADV, 2021.Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod ADRead publication: JEADV 2021 Related Contact Us Tel: +44 (0)161 306 1896 Email:...
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR
JEADV, 2021.Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ; Ormerod AD; BADBIR Study Group.Read publication: JEADV 2021 Related Contact Us Tel: +44 (0)161 306 1896 Email:...
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
JAMA Dermatol, 2020.Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group.Read publication: JAMA Dermatol Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find...
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology
Br J Dermatol, 2020.Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM; BADBIR Study Group.Read publication: Br J Dermatol Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find Us The University of ManchesterFirst Floor...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Br J Dermatol, 2020.Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group.Read publication: Br J Dermatol Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find...
Amendment 12
Study Amendment 12 to BADBIR has implementation date of 06/10/2020. Documents in this amendment You can download all of the files for this amendment in one go using the link below (.zip file). If you would like the tracked changes versions of the documents to see...
Ethics Progress Report: 2020
Read the 2020 Ethics Progress Report. Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find Us The University of ManchesterFirst Floor Bright BuildingManchester Science ParkManchesterM15 6GZ Connect With...
Patient newsletter: 2020
This newsletter is also available in a full-colour, printable PDF format: Download the Patient Newsletter 2020 (PDF) WelcomeThe British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) is a drug safety register seeking to assess the...
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
Br J Dermatol, 2020.Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN; Burden AD, Smith CH; BADBIR study group and the PSORT consortium.Read publication: Br J Dermatol Related...
Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study
J Eur Acad Dermatol Venereol, 2020.Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM; BADBIR Study Group.Read publication: J Eur Acad Dermatol Venereol Related Contact Us Tel: +44...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
